Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) will likely be announcing its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Atea Pharmaceuticals Stock Performance

Shares of Atea Pharmaceuticals stock opened at $4.82 on Wednesday. The stock’s fifty day moving average is $3.99 and its 200 day moving average is $3.46. Atea Pharmaceuticals has a one year low of $2.45 and a one year high of $4.89. The stock has a market cap of $376.59 million, a P/E ratio of -2.72 and a beta of 0.21.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AVIR. JPMorgan Chase & Co. lifted its position in shares of Atea Pharmaceuticals by 118.6% in the fourth quarter. JPMorgan Chase & Co. now owns 1,348,294 shares of the company’s stock worth $4,813,000 after buying an additional 731,443 shares in the last quarter. Millennium Management LLC increased its stake in Atea Pharmaceuticals by 179.2% in the 3rd quarter. Millennium Management LLC now owns 487,223 shares of the company’s stock worth $1,413,000 after acquiring an additional 312,733 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Atea Pharmaceuticals by 185.8% during the 3rd quarter. Bank of America Corp DE now owns 313,644 shares of the company’s stock worth $910,000 after acquiring an additional 203,905 shares in the last quarter. Opaleye Management Inc. purchased a new position in shares of Atea Pharmaceuticals in the fourth quarter valued at $642,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Atea Pharmaceuticals by 38.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 472,522 shares of the company’s stock valued at $1,687,000 after purchasing an additional 132,382 shares in the last quarter. Hedge funds and other institutional investors own 86.67% of the company’s stock.

Analyst Upgrades and Downgrades

AVIR has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Wednesday, January 21st. Evercore upgraded shares of Atea Pharmaceuticals to a “strong-buy” rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.